Choosing St. Jude | Eligibility Requirements (ĐỌC KỸ)

Note: If you are a Referring Physician, please visit our physician referral information page.

St. Jude is a global resource focused solely on research and treatment for children with cancer and other life-threatening diseases. This focused approach to finding cures and saving children makes us different from most children’s hospitals.

What’s different about treatment at St. Jude?

St. Jude is continuously developing new, improved treatments for children with cancer and other life-threatening diseases. These new treatments are offered through clinical research trials that are also called research studies or protocols. Most of our patients—including more than 90 percent of our patients with cancer—are enrolled on a research study. We treat conditions that do not respond well to current standard treatments, offering new treatments we’ve developed that could prove to be more effective or have fewer side effects.

How are patients accepted?

In general, a child must be eligible for one of our open clinical research studies in order to be accepted for treatment at St. Jude. Each study specifies the age range and exact medical criteria for acceptance in that study. Medical criteria may include things like the exact type and stage of the child’s disease. If a child’s condition does not match an open study, we offer consultation and other options explained later in this section.

If your child has been diagnosed with a brain tumor, please see our eligibility requirements for brain tumor patients.

A child must also have a referral from a physician or qualified medical professional who can provide St. Jude with medical information. Every study has specific and often different requirements. For this reason, it is important that your child’s doctor contact us. For some of our studies, children can only be accepted if they have not yet begun treatment, so encourage you to have your medical provider contact us as early as possible.

Children who qualify for open clinical research studies are accepted regardless of race, sex, nationality, ethnicity, religion, or the family’s ability to pay. St. Jude must also have sufficient capacity within the treatment programs the patient needs in order to accept a new patient.

What if my child is not eligible for a St. Jude research study?

St. Jude has been instrumental in developing and improving many treatments that are now considered the standard therapy for pediatric cancer and other catastrophic diseases. If your child is not eligible for a St. Jude research study, we can help you identify a hospital near you offering an appropriate treatment program and we can provide ongoing consultation with the medical team caring for your child at that hospital.

If you live in the U.S. or one of its territories and do not live within a reasonable driving distance* of a hospital offering an appropriate treatment program, your child may qualify for treatment at St. Jude providing your child has a disease we are able to treat and we have sufficient capacity within the treatment program. If you do not live in the U.S. and your child does not qualify for a research study, we may be able to offer consultation. Please ask your doctor to contact our Referring Physicians Office for information.

What about insurance?

No family ever pays St. Jude for anything. Insurance coverage is not needed and is not a factor in accepting patients. If your child is accepted for admission and you do not have insurance, St. Jude will cover all treatment costs. If you have insurance, St. Jude will work with your health insurance and will cover all treatment costs not covered by your insurance.

*To determine reasonable driving distance, St. Jude considers a variety of geographic factors.

Patient Acceptance Policy (ĐỌC KỸ)

URL: http://www.stjude.org/stjude/v/index.jsp?vgnextoid=a738588865e70110VgnVCM1000001e0215acRCRD&vgnextchannel=8f61bfe82e118010VgnVCM1000000e2015acRCRD

Note: If you are not a referring physician, please read our Eligibility Requirements.

St. Jude Children’s Research Hospital welcomes referrals of children and adolescents with newly diagnosed, untreated or suspected cancer; HIV infections; or certain hematologic or genetic diseases.  Patients are accepted based on the eligibility to enroll in an open St. Jude Children's Research Hospital clinical research protocol.

In addition, previously treated patients who have received treatment elsewhere may be accepted on an individual case basis when there is a potential for protocol eligibility on ongoing studies, relapse studies, bone marrow transplantation protocols or Phase I-II studies. Patients with genetic disorders, hematologic diseases, or HIV infection may be accepted anytime in their disease history based on protocol eligibility or potential to contribute to research projects.

Patients are enrolled on medical research studies (clinical trials) designed to provide the best available care while answering important research questions.

You can reach the physician referral line to discuss your patient by calling 1-866-278-5833. If your call is urgent, you may page us at 1-800-349-4334. If your call is not urgent, please leave a message and we will return your call as soon as possible.

A physician may call if you have questions about difficult diagnostic or medical management cases. St. Jude provides formal consultations to treating physicians free of charge. However, for a formal consultation, you should send complete, detailed medical information to St. Jude. If you prefer, you can send us a detailed medical history, copies of relevant diagnostic imaging evaluations, and pathology/histological material; our multidisciplinary groups will discuss your patient's case and offer recommendations. (For a complete list of the required medical information, call 866-2STJUDE.) St. Jude does not bring patients to Memphis for consultation unless those patients are likely to be eligible for St. Jude protocols.

After the initial therapy has been completed, patients are typically managed in close collaboration with their private physicians. St. Jude experts in hematology, oncology, bone marrow transplantation, genetic diseases and infectious diseases are available at all times for consultation regarding possible side effects of therapy, signs of recurring disease, or other questions related to patient management on mutual patients on St. Jude clinical trials. Close contact with our patients' referring physician is important to us and necessary for our patients' safety. If you have patients on our studies and need to contact someone about them, please call 1-866-278-5833 and ask to speak to the St. Jude attending physician for your patient.

All patients accepted for treatment at St. Jude are treated without regard to the family's ability to pay. St. Jude covers all costs of treatment at St. Jude beyond those reimbursed by third-party insurers, and total costs at St. Jude when no insurance is available. St. Jude also provides assistance with transportation costs and local living expenses during treatments.

Leukemia / Lymphoma Protocols / Clinical Studies (ĐỌC KỸ)

URL: http://www.stjude.org/stjude/v/index.jsp?vgnextoid=8b41bfe82e118010VgnVCM1000000e2015acRCRD

(Cái này sẽ giúp em, liệt kê Vinh vào giai đoạn nào của Leukemia, em đọc kỹ nhé)

For information on these and other studies, referring physicians may e-mail protocolinfo@stjude.orgor call toll free physician referral line, 1-888-226-4343. If you are not a physician, please e-mailinfo@stjude.org for information on St. Jude studies.

ALLR18

A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

For: Relapsed or refractory precursor B-cell acute lymphoblastic leukemia and lymphoma

AML08

A Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy and of Natural Killer Cell Transplantation Versus Conventional Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

For: acute myeloid leukemia (AML)

ANGIO1

Phase I Study of Bevacizumab and Sorafenib Combined with Low Dose Cyclophosphamide in Patients with Refractory Solid Tumors and Leukemia

For: Recurrent or refractory solid tumors and leukemias

HIFLEX

A Reduced Intensity Conditioning Regimen with CD3-Depleted Hematopietic Stem Cells to Improve Survival for Patients with Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation

For: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Paroxysmal Nocturnal Hemoglobinuria (PNH), Hodgkin lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome (MDS)

HOD08

Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma

For: Hodgkin lymphoma

HODLP

First International Inter-Group Study for Nodular Lymphocyte Predominant Hodgkin's Lymphoma in Children and Adolescents

For: Lymphocyte predominant Hodgkin lymphoma

INFT2

HLA - Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less than 2 Years of Age with Hematologic Malignancies

For: Leukemias (high risk hematologic malignancies)

NHL16

Study for Newly Diagnosed patients with Acute Lymphoblastic Lymphoma

For: Acute lymphoblastic leukemia

NKCD19

Pilot Study of Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia

For: Acute lymphoblastic leukemia (ALL)

NKEXP

Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors

For: Refractory or relapsed leukemia (AML, T-ALL, CML, JMML), T-cell lymphoma, myelodysplastic syndrome, Ewing sarcoma (ESFT), rhabdomyosarcoma (RMS)

RADIANT

A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children with Relapsed or Refractory Solid Tumors or Lymphomas

For: Relapsed or refractory solid tumors or lymphomas

RELHEM

A Pilot Pharmacokinetic, Pharmacodynamic, and Feasibility Study of Sorafenib in Combination with Cytarabine and Clofarabine in Patients with Refractory or Relapsed Hematologic Malignancies

For: Acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), acute lymphoblastic leukemia (ALL), infantile leukemia (both AML and ALL), AML w/prior myelodysplastic syndrome (MDS), myelodysplastic / myeloproliferative neoplasms, biphenotypic leukemia

SJBC3

Mature B-Cell Lymphoma and Leukemia Study III

For: Leukemia and lymphoma

TOTXVI

Total Therapy Study XVI for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia

For: Acute Lymphoblastic Leukemia

Non St. Jude Protocols

ADV912

A Phase I/II Study of PF-02341066, An Oral Small Molecule Inhibitor Of Anaplastic Lymphoma Kinase (ALK) And C-Met, In Children With Relapsed/Refractory Solid Tumors And Anaplastic Large Cell Lymphoma

For: Relapses/refractory solid tumors and anaplastic large cell lymphoma

ADV921

A Phase II Study of MLN8237 (IND#102984), A Selective Aurora Kinase Inhibitor, In Children with Recurrent/Refractory Solid Tumors and Leukemias (ADVL0921)

For: recurrent or refractory solid tumors (including rhabdoid and malignant germ cell tumors of the CNS) and leukemias

ALL1121

A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Pediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia

For: Relapsed or refractory B-precursor acute lymphoblastic leukemia

AML5P1

Killer Immunoglobulin-Like Receptor (KIR) Incompatible Hematopoietic Cell Transplantation (HCT) for Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children’s Oncology Group (COG) Study (AAML05P1)

For: Refractory and relapsed acute myelogenous leukemia (AML)

CD22AB

A phase I, multi-center, dose escalation study of CAT-8015 in children, adolescents and young adults with refractory CD22+ acute lymphoblastic leukemia (ALL), or non-Hodgkin’s Lymphoma (NHL) (CAT-8015-1004)

For: acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), including lymphoblastic lymphoma, Burkitt’s lymphoma, and large cell lymphoma

DVALL

A Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL (TACL protocol T2009-003)

For: Relapsed ALL

LDTAM

Low-dose Tamoxifen in Hodgkin Lymphoma Survivors for Breast Cancer Risk Reduction: A Phase IIB Randomized Placebo-Controlled Trial

For: For survivors of Hodgkin lymphoma

NCBP01

A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

For: Leukemia and other blood diseases

NECTAR

A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide) in T-ALL Relapse: A Joint Study of TACL and POETIC

For: Leukemia

PANSTAT

A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies

For: Relapsed acute lymphoblastic leukemia [ALL], acute myelogenous leukemia [AML], Hodgkin disease [HD] and non-Hodgkin’s lymphomas [NHL]

Current Clinical Trials (ĐỌC KỸ)

(đọc cái này kỹ nhé)

url: http://www.stjude.org/stjude/v/index.jsp?vgnextoid=32d2bd5496c8c310VgnVCM100000290115acRCRD&vgnextchannel=c280bfe82e118010VgnVCM1000000e2015acRCRD

Current Clinical Trials

Our "bench-to-bedside" approach to finding cures for the catastrophic diseases of childhood allows St. Jude patients more efficient access to the latest research findings available. Our clinical trials are freely shared with physicians and healthcare institutions throughout the world.

We are actively recruiting for specific clinical studies. Patients must be referred by their physician. See Refer a Patient to St. Jude to find out how to refer a patient to St. Jude or for referral, consultation and treatment policies. Parents who want to know if their children are eligible to be treated at St. Jude should have their children’s physician call the toll free number below.

Note: There may not be open clinical trials in place for all of the conditions, stages or treatment phases of every disease listed below. For information about whether a specific disease is currently being treated in a clinical trial at St. Jude,  about other catastrophic diseases in the categories listed here or to determine if a child is eligible for treatment at St. Jude, physicians are encouraged to contact us toll free at 1-888-226-4343 or request an online referral.   (See our Mobile-friendly Physician Referral Form.)

• Brain Tumors • Hematological Disorders • Infectious Diseases • Leukemias / Lymphomas • Phase I & II Studies • Radiology • Solid Tumors • Stem Cell / Bone Marrow Transplant • Supportive Studies • Vaccines

Childrens Hospital Los Angeles Awarded $2.5 Million to Develop Nanotherapy Against Acute Lymphocytic Leukemia

URL: http://www.chla.org/site/apps/nl/newsletter2.asp?c=ipINKTOAJsG&b=6089699#.UYnNuKJaXjI

Fatih Uckun, MD, PhD of the Saban Research Institute of Childrens Hospital Los Angeles has been awarded $2.5 million from the National Cancer Institute(NCI) to support development of a new class of anti-cancer drugs against acute lymphoblastic leukemia (ALL), the most common form of cancer in children and adolescents. 

CONTACT: Ellin Kavanagh at (323) 361-8505

LOS ANGELES (August 2, 2010) – Fatih Uckun, MD, PhD of the Saban Research Institute of Childrens Hospital Los Angeles has been awarded $2.5 million from the National Cancer Institute(NCI) to support development of a new class of anti-cancer drugs against acute lymphoblastic leukemia (ALL), the most common form of cancer in children and adolescents. 

Uckun and his colleagues have been developing rationally-designed and cancer-specific nanomedicines that target the survival machinery of leukemia cells as potent cancer “smart bombs”.  “Our long-term goal is to translate recent research discoveries in nanotechnology and biotherapy into effective patient-tailored treatment programs for the most common form of childhood cancer,” explains Dr. Uckun, who is also a professor of research pediatrics at the Keck School of Medicine of the University of Southern California. The work will be accomplished in close collaboration with other member institutions of the NCI Alliance for Nanotechnology in Cancer.

Nanotechnology refers to science and engineering performed on a molecular level.  Applied to oncology, nanotherapeutics can target the infrastructure of cancer. 

“The development of these nanomedicines will be a significant step forward to overcome chemotherapy resistance in childhood leukemia,” added Dr. Paul Gaynon, professor of pediatrics and medical director of the Therapeutic Advances in Childhood Leukemia consortium.

“We are excited about these novel nanomedicines because they may provide the foundation for therapeutic innovation against childhood cancer,” said Dr. Stuart Siegel, director of the Children’s Center for Cancer and Blood Diseases at Childrens Hospital Los Angeles. 

The Saban Research Institute at Childrens Hospital Los Angeles is among the largest and most productive pediatric research facilities in the United States, with 100 investigators at work on 186 laboratory studies, clinical trials and community-based research and health services. The Saban Research Institute is ranked eighth in National Institutes of Health funding among children’s hospitals in the United States.

Founded in 1901, Childrens Hospital Los Angeles is one of the nation’s leading children’s hospitals and is acknowledged worldwide for its leadership in pediatric and adolescent health. Childrens Hospital Los Angeles is one of only seven children’s hospitals in the nation – and the only children’s hospital on the West Coast – ranked for two consecutive years in all 10 pediatric specialties in the U.S. News & World Report rankings and named to the magazine’s “Honor Roll” of children’s hospitals.

Childrens Hospital Los Angeles is a premier teaching hospital and has been affiliated with the Keck School of Medicine of the University of Southern California since 1932.

Research Consortium at Childrens Hospital Los Angeles Receives $410,000 to Study Leukemia and Lymphoma

URL: http://www.chla.org/site/apps/nl/newsletter2.asp?c=ipINKTOAJsG&b=6089699#.UYnNuKJaXjI

Award will fund phase I study targeting specific genetic mutations in children with leukemia or lymphoma

CONTACT:  Ellin Kavanagh at (323) 361-8505

LOS ANGELES (July 16, 2010) – J. Eric Bubbers, PhD, of the Saban Research Institute at Childrens Hospital Los Angeles, has received a $410,000 grant from Phase One Foundation.  The award will fund a “first in childhood leukemia” multi-site study in children with relapsed or refractory acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML).  Dr. Bubbers is the administrative director of Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL), an academic research consortium consisting of 33 member institutions in four countries. 

“Both ALL and AML are cancers of the blood and bone marrow, with ALL being the most common cancer occurring in children,” explains Dr Bubbers.  “These diseases begin when a single cell changes from a normal cell to a cancer cell.  Patients receive treatment – chemotherapy and/or radiation – with the hope of achieving remission.  But sometimes that doesn’t happen, or the remission doesn’t last.” 

A child is in remission when he or she is not showing any signs or symptoms of disease.  But sometimes the cancer cells return.  This condition is called relapse.  Other patients undergo treatment but not all the cancer cells are gone from their body.  In this case, the patient has refractory disease.  When a child has relapsed or refractory disease, different treatments may be required.

The TACL consortium is studying a new alternative treatment for these patients.  Gene-targeted therapy, a type of personalized medicine, is based on the specific type of chromosomal changes occurring in a patient’s cells.  Certain genetic mutations, those of FLT3 and c-Kit, are associated with a particularly poor prognosis. This multi-center study will use a new drug that has been expressly optimized to inhibit FLT3 and c-Kit and has been effective in treating adults with these diseases.  The goal of the phase I study is to determine a safe and biologically-active dose in young patients.

The TACL study chair is Todd Cooper, DO, of Children’s Healthcare of Atlanta, Emory University, and the vice-chair is Pat Brown, MD, of Johns Hopkins University.  TACL can be reached at their website: www.tacl.us.

The Phase One Foundation is a non-profit organization dedicated to supporting phase I clinical research and treatment programs for patients with cancer.  Federal funding is often only available after viable early results, so this type of early-stage funding is crucial in the development of innovative therapies.

The Saban Research Institute at Childrens Hospital Los Angeles is among the largest and most productive pediatric research facilities in the United States, with 100 investigators at work on 186 laboratory studies, clinical trials and community-based research and health services. The Saban Research Institute is ranked eighth in National Institutes of Health funding among children’s hospitals in the United States.

Founded in 1901, Childrens Hospital Los Angeles is one of the nation’s leading children’s hospitals and is acknowledged worldwide for its leadership in pediatric and adolescent health. Childrens Hospital Los Angeles is one of only seven children’s hospitals in the nation – and the only children’s hospital on the West Coast – ranked for two consecutive years in all 10 pediatric specialties in the U.S. News & World Report rankings and named to the magazine’s “Honor Roll” of children’s hospitals.

Childrens Hospital Los Angeles is a premier teaching hospital and has been affiliated with the Keck School of Medicine of the University of Southern California since 1932.

 Visit our website: www.ChildrensHospitalLA.org

Financial Assistance Policy Fro St. Jude Children's Research Hospital

URL http://www.stjude.org/stjude/v/index.jsp?vgnextoid=c233dab3b695b210VgnVCM1000001e0215acRCRD&vgnextchannel=e463dab3b695b210VgnVCM1000001e0215acRCRD&SearchUrl=search_results.jsp&QueryText=financial%20assistance

Financial Assistance Policy

St. Jude Children’s Research Hospital is a scientific research and treatment center dedicated to developing cures for pediatric cancers and other catastrophic childhood diseases.  The vast majority of children who are accepted for treatment at St. Jude are enrolled in research studies, based upon referrals from their local physician and according to St. Jude’s acceptance policy.  Providing treatment according to prospectively designed clinical trials that are interfaced with laboratory research has been critical to advancements made in the treatment of childhood cancers at St. Jude, and all St. Jude discoveries are shared freely with the world. All children are treated at St. Jude regardless of race, religion, or ability to pay.  A billing system is maintained for each patient, but bills are not sent to any patient.  If the patient has insurance, the hospital bills the patient’s health insurance plan.  By collecting insurance payments that would be due had the patient received treatment at nearly any other hospital in the country, and with the assistance of St. Jude donors, St. Jude has been able to use our financial resources to conduct cutting-edge research and cover treatments, copays, deductibles, and coinsurance that are not covered by insurance. This has allowed our clinical and translational research to make major advances in cure rates for childhood cancers and to improve the treatment of sickle cell disease and other catastrophic diseases in children.  Thus, any legal obligation of payment for a patient’s costs that are not covered by insurance is covered by the generous assistance of St. Jude donors with the result that St. Jude does not ask a patient to pay. 

The method of applying for financial assistance at St. Jude is universal and conforms to the principles stated.  All St. Jude patients receive the same financial assistance.  St. Jude does not pursue collection efforts against any patient family. 

This Financial Assistance Policy is required to be made public by every hospital in the United States as part of the Patient Protection and Affordable Care Act (PPACA).  Regulatory and legal interpretations of the impact of PPACA are evolving.  However, for purposes of admission to St. Jude, once a patient is accepted for treatment, this policy is not altered.